Valuation: Cell Source, Inc.

Market Cap 24.41M 21.42M 19.95M 18.35M 34.4M 2.33B 34.99M 237M 92.64M 1.16B 91.64M 89.66M 4B P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 34.92M 30.64M 28.54M 26.25M 49.2M 3.34B 50.05M 339M 133M 1.65B 131M 128M 5.72B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day-2.10%
1 week+2.91%
Current month+5.85%
1 month+0.40%
3 months+7.75%
6 months-6.44%
Current year+64.66%
1 week 0.53
Extreme 0.531
0.84
1 month 0.53
Extreme 0.531
0.96
Current year 0.41
Extreme 0.4134
2.25
1 year 0.3
Extreme 0.3022
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2014
Director TitleAgeSince
Chairman 77 18/05/2015
Director/Board Member 82 25/03/2021
Director/Board Member 72 10/03/2022
Date Insider Type Main position Quantity % Market Cap.
9/8/21 Others

Director

800,000 2.4492%
30/6/21 Others

Director

19,440 0.0595%
30/6/21 Others

Director

4,860 0.0149%
Change 5-day change 1-year change 3-year change Capi.($)
-2.10%+2.91%+105.83%+39,104.76% 55.94M
-0.34%+1.45%+49.57%+68.36% 55.01B
-1.32%-2.71%+34.27%+77.57% 54.24B
+1.49%+0.13%-18.03%-13.94% 23.38B
-0.57%-4.13%+2.34%+387.73% 22.57B
+2.07%+1.39%+17.20%-10.70% 20.19B
-0.38%-0.65%+29.41%-31.88% 17.86B
-2.14%-3.75%+26.23%+558.64% 15.5B
-6.69%-5.11%+169.13%+304.89% 14.2B
+1.25%+0.69%+27.30%+184.69% 14.2B
Average -0.88%-0.31%+44.33%+4,063.01% 23.72B
Weighted average by Cap. -0.61%-0.52%+34.95%+140.83%

Financials

2023 2024
Net sales - -
Net income -5.32M -4.67M -4.35M -4M -7.5M -508M -7.63M -51.59M -20.19M -252M -19.98M -19.55M -871M -4.51M -3.96M -3.69M -3.39M -6.36M -431M -6.47M -43.75M -17.13M -214M -16.94M -16.58M -739M
Net Debt 9.27M 8.14M 7.58M 6.97M 13.07M 886M 13.29M 89.91M 35.19M 439M 34.82M 34.06M 1.52B 10.51M 9.22M 8.59M 7.9M 14.81M 1B 15.06M 102M 39.88M 498M 39.45M 38.6M 1.72B
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
1
Date Price Change Volume
28/07/26 USD 0.8233 -2.10% 300
27/07/26 USD 0.8410 +29.38% 200
24/07/26 USD 0.6500 +0.78% 400
23/07/26 USD 0.6450 -19.38% 6,500
21/07/26 USD 0.8000 +25.00% 504
  1. Stock Market
  2. Stocks
  3. CLCS Stock